ENAM 基因与 T 分类相关，可抑制肾透明细胞癌的增殖。

ENAM gene associated with T classification and inhibits proliferation in renal clear cell carcinoma.

机构信息

The State Key Laboratory of Reproductive Medicine, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.

Department of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Huinan, Pudong, Shanghai 201399, China.

出版信息

Aging (Albany NY). 2021 Feb 3;13(5):7035-7051. doi: 10.18632/aging.202558.

The potential involvement of T classification-related genes in renal clear cell carcinoma (ccRCC) must be further explored. Public data were obtained from The Cancer Genome Atlas (TCGA) database. An overall survival (OS) predictive model was developed and validated (TCGA train, 5 years, AUC = 0.73, 3 years, AUC = 0.73, 1 year, AUC = 0.76; TCGA test, 5 years, AUC = 0.74, 3 years, AUC = 0.65, 1 year, AUC = 0.73; TCGA all, 5 years, AUC = 0.72, 3 years, AUC = 0.71, 1 year, AUC = 0.75). Finally, ENAM was selected for further analysis. experiment indicated that ENMA is downregulated in ccRCC, and its knockdown could promote proliferation in two cancer cell lines (OSRC-2 and SW839). Immune infiltration analysis revealed that ENAM could remarkably increase the content of cytotoxic cells, NK CD56 cells, NK cells and CD8+ T cells in the tumor immune microenvironment, which may be one reason for its tumor-inhibiting effect. In summary, ENAM may suppress cell proliferation in ccRCC and can be used as a potential reference value for the relief and immunotherapy of ccRCC.

必须进一步探讨 T 分类相关基因在肾透明细胞癌（ccRCC）中的潜在作用。公共数据来自癌症基因组图谱（TCGA）数据库。开发并验证了总生存期（OS）预测模型（TCGA 训练，5 年，AUC=0.73，3 年，AUC=0.73，1 年，AUC=0.76；TCGA 测试，5 年，AUC=0.74，3 年，AUC=0.65，1 年，AUC=0.73；TCGA 全部，5 年，AUC=0.72，3 年，AUC=0.71，1 年，AUC=0.75）。最后，选择 ENAM 进行进一步分析。实验表明，ENMA 在 ccRCC 中表达下调，其敲低可促进两种癌细胞系（OSRC-2 和 SW839）的增殖。免疫浸润分析表明，ENAM 可显著增加肿瘤免疫微环境中细胞毒性细胞、NK CD56 细胞、NK 细胞和 CD8+T 细胞的含量，这可能是其抑制肿瘤的原因之一。总之，ENAM 可能抑制 ccRCC 中的细胞增殖，可作为 ccRCC 缓解和免疫治疗的潜在参考价值。